Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Carcinoma, Renal Cell 2Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × vorolanib × 1 year × Clear all
NCT07386158 2026-02-04

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Sun Yat-sen University

Phase 2 Recruiting
21 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04373369 2025-11-03

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Terminated
11 enrolled 10 charts
Thoracic

Small Cell Lung Carcinoma

NCT07047001 2025-07-09

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡